QualityDipStocks / Health Care · Medical Specialities
Natera NTRA
Outside our quality screen, so we don’t track its dips. It’s 5% below its 52-week high.
Outside our quality screen, 12% over its Market Value. No fair value estimate for now: its free cash flow is near zero.
- Fair value est.
- n/a
- Market Value
- $371.10price +12%
- Off 52-wk high
- −5%
- Risk vs market
- Above marketbeta 1.30
3 bullish · 5 bearish See why
Key levels
Every level vs today’s $414.30
- 52-wk lowlowest close, 1 year$182.65−55.9%
- Market Valueavg paid since Aug 6$371.10−10.4%
- PriceFri Oct 30 close$414.30you are here
- 52-wk highhighest close, 1 year$436.00+5.2%
Fair value estimate
No estimate for NTRA: free cash flow is barely positive ($0.59 a share); a DCF says little. We’d rather show nothing than a made-up number.
Risk vs market
How risk vs market is measured
One year of daily returns (Oct 30 to Oct 30, 252 sessions). Beta = how much NTRA moved for each 1% move in the S&P 500 (SPY); 1.0 moves with the market. Volatility is the yearly standard deviation of daily returns. Past behavior, not a forecast.
Swings more than the market, and its own price swings are 3.8× the S&P 500’s.
- Beta vs S&P 500
- 1.30
- Volatility
- 49% vs 13% SPY
- Correlation SPY
- 0.34
- Correlation QQQ
- 0.30
Bull vs bear
Rule-based from the data on this page, strongest first. Not advice.
Top bullish points 3 of 5
ProfitabilityOperating margin widened to −13.4% in FY2025 from −41.2% in FY2023 (SEC filings).
GrowthSales compounded 41% a year from FY2022 to FY2025.
GrowthSales grew 38% to $2.7B over the last 12 months vs the 12 months before (SEC filings).
Top bearish points 5 of 5
Balance sheetOperating income covers interest only -75.9× over the last 12 months.
ProfitabilityLost $192M over the last 12 months (net income, SEC filings).
ProfitabilityLoses money at the operating line: −11% operating margin over the last 12 months.
QualityDoesn’t pass our quality screen: ROE under 12% and ROIC under 10%.
ValuationTrades 11.6% above its Market Value of $371.10, the average price paid since the Aug 6 filing.
Who’s talking about it
Notable investors, executives, analysts and public figures on Natera in the last 48 hours. Headlines as published, each linked. Their words, not ours.
No notable mentions in the last 48 hours. Checked Nov 1, 9:09 PM ET.
Compare with peers
Closest in size in Medical Specialities
All fundamentals
FCF yield 0.1% · ROE -13% · Sales +38%
Valuation
- P/E
- n/aloss over the last 12 months
- Price / FCF
- n/an/m: free cash flow near zero
- FCF yield
- 0.1%
- EV / EBITDA
- n/aD&A or debt not tagged in SEC data
- Price / sales
- 21.93×
- Price / book
- 32.59×
- Market cap
- $59.4Bprice × diluted shares
- Enterprise value
- n/anot reported in its SEC filings
Growth
- Revenue, 12 months
- $2.7B
- Sales growth, 12 months
- +37.8%vs the 12 months before
- Sales growth, 3 yrs
- +41.1%/yrfrom FY2022
- Diluted EPS, 12 months
- −$1.35
- EPS growth, last FY
- n/afewer than two years of diluted EPS
- Net income, 12 months
- −$192M
- Net income growth
- n/anot reported in its SEC filings
Profitability
- Gross margin
- n/agross profit isn't reported (common for service and financial companies)
- Operating margin
- −10.7%
- Net margin
- −7.1%
- FCF margin
- 3.1%
- Return on equity
- −13%
- Return on invested capital
- n/aoperating income, debt, equity or cash not tagged
Balance sheet
- Cash & short-term inv.
- $1.1B
- Total debt
- n/anot reported in its SEC filings
- Net cash
- n/acash or debt not tagged in SEC data
- Debt / equity
- n/adebt or equity not tagged in SEC data
- Interest coverage
- -75.9×operating income / interest
Cash flow & returns
- Free cash flow, 12 months
- $84M
- FCF growth, 12 months
- −19%
- Dividend yield
- 0%
- Payout ratio
- n/anot reported in its SEC filings
- Buybacks, 12 months
- n/anot reported in its SEC filings
- Share count, 1 year
- +5.1%diluted shares vs a year ago
- Stock-based comp
- $381M
Trailing 12 months to Jun 30, 2026; balance sheet at Jun 30, 2026. From Natera’s SEC filings. Sparklines show up to six fiscal years. n/a means we don’t hold that number, with the reason. How each is computed.
Valuation details
MV $371.10 · FCF value $8.25
Setup & signals
No setup armed
No setup armed, so there’s no trigger or stop to track yet. Reversal signal rules only run on companies that pass our quality screen.
Momentum & 52-week range
RSI 57 · 5 days +2.6%
The business
FCF $0.1B · Sales +38%
- Free cash flow, 12 months$0.1B
- Free-cash-flow yield0.1%
- Free-cash-flow margin2%
- Gross margin65%
- Operating margin−11%
- Return on invested capital−12%
- Return on equity−12%
- Sales growth (latest quarter vs year-ago quarter)+38%
Next report
Nov 5
- DateThu Nov 5, after the close
- Consensus EPS($0.17)
- Year-ago EPS($0.64)
- QuarterSep/2026
From Nasdaq’s earnings calendar. A report resets Market Value.
Information only, not investment advice. Fair value estimates and talking points are rule-based model output from public data and can be wrong; stop levels are reference points, not orders. How every number is computed.
NTRA is outside our quality screen
One text when a published rule fires on one of the 333 quality companies we track: the ticker, the price, the stop and a link to the numbers. Nothing else.